Question

A 69-year-old man with COPD (FEV₁ 40% predicted) has two moderate exacerbations in the past year despite using a long-acting muscarinic antagonist (LAMA) daily. He remains dyspnoeic on exertion. According to the 2023 CTS COPD pharmacotherapy guideline, which adjustment is most appropriate?

Accepted Answer

Start triple therapy with single-inhaler ICS/LABA/LAMA

Answer

Continue LAMA monotherapy; no change needed

Answer

Switch to short-acting bronchodilator monotherapy

Answer

Escalate to dual long-acting bronchodilator (LAMA/LABA)

Answer

Add inhaled corticosteroid alone

Practice question

A 69-year-old man with COPD (FEV₁ 40% predicted) has two moderate exacerbations in the past year despite using a long-acting muscarinic antagonist (LAMA) daily. He remains dyspnoeic on exertion. According to the 2023 CTS COPD pharmacotherapy guideline, which adjustment is most appropriate?